Alpha 2.0
Login Register
» Authors » Gina Vaccaro

Gina Vaccaro

Explore the profile of Gina Vaccaro including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 7
Citations 812
Followers 0
Related Specialties
Oncology
General Surgery
Pharmacology
Top 10 Co-Authors
Raed Al-Rajabi
Charles D Lopez
Catherine W Rehder
Do-Youn Oh
Andrew L Coveler
Adrian G Murphy
Madeline J Griffith
Carlos M DeCastro
Meenal Sinha
Jeannie Louie
Published In
JAMA Oncol
Lancet Oncol
Am J Hematol
Ann Surg
J Immunother Cancer
Affiliations
Soon will be listed here.
Recent Articles
1.
Modulation of myeloid and T cells in vivo by Bruton's tyrosine kinase inhibitor ibrutinib in patients with metastatic pancreatic ductal adenocarcinoma
Sinha M, Betts C, Zhang L, Griffith M, Solman I, Chen B, et al.
J Immunother Cancer . 2023 Jan; 11(1). PMID: 36593070
Background: In preclinical studies of pancreatic ductal adenocarcinoma (PDAC), ibrutinib improved the antitumor efficacy of the standard of care chemotherapy. This led to a phase 1b clinical trial to determine...
2.
Galunisertib plus neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer: a single-arm, phase 2 trial
Yamazaki T, Gunderson A, Gilchrist M, Whiteford M, Kiely M, Hayman A, et al.
Lancet Oncol . 2022 Aug; 23(9):1189-1200. PMID: 35952709
Background: TGF-β is an immunosuppressive cytokine that is upregulated in colorectal cancer. TGF-β blockade improved response to chemoradiotherapy in preclinical models of colorectal adenocarcinoma. We aimed to test the hypothesis...
3.
Efficacy of Preoperative mFOLFIRINOX vs mFOLFIRINOX Plus Hypofractionated Radiotherapy for Borderline Resectable Adenocarcinoma of the Pancreas: The A021501 Phase 2 Randomized Clinical Trial
Katz M, Shi Q, Meyers J, Herman J, Chuong M, Wolpin B, et al.
JAMA Oncol . 2022 Jul; 8(9):1263-1270. PMID: 35834226
Importance: National guidelines endorse treatment with neoadjuvant therapy for borderline resectable pancreatic ductal adenocarcinoma (PDAC), but the optimal strategy remains unclear. Objective: To compare treatment with neoadjuvant modified FOLFIRINOX (mFOLFIRINOX)...
4.
A Phase 3 Randomized Clinical Trial of Chemotherapy With or Without Algenpantucel-L (HyperAcute-Pancreas) Immunotherapy in Subjects With Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer
Hewitt D, Nissen N, Hatoum H, Musher B, Seng J, Coveler A, et al.
Ann Surg . 2021 Feb; 275(1):45-53. PMID: 33630475
Objectives: To compare the efficacy and safety of algenpantucel-L [HyperAcute-Pancreas algenpantucel-L (HAPa); IND# 12311] immunotherapy combined with standard of care (SOC) chemotherapy and chemoradiation to SOC chemotherapy and chemoradiation therapy...
5.
Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study
Abou-Alfa G, Sahai V, Hollebecque A, Vaccaro G, Melisi D, Al-Rajabi R, et al.
Lancet Oncol . 2020 Mar; 21(5):671-684. PMID: 32203698
Background: Fibroblast growth factor receptor (FGFR) 2 gene alterations are involved in the pathogenesis of cholangiocarcinoma. Pemigatinib is a selective, potent, oral inhibitor of FGFR1, 2, and 3. This study...
6.
Chemoradiation for Locally Advanced Unresectable Pancreatic Cancer-What Now?
Vaccaro G, Lopez C
JAMA Oncol . 2016 Aug; 3(6):850-851. PMID: 27490715
No abstract available.
7.
Clinical and molecular predictors of disease severity and survival in chronic lymphocytic leukemia
Weinberg J, Volkheimer A, Chen Y, Beasley B, Jiang N, Lanasa M, et al.
Am J Hematol . 2007 Jul; 82(12):1063-70. PMID: 17654680
Several parameters may predict disease severity and overall survival in chronic lymphocytic leukemia (CLL). The purpose of our study of 190 CLL patients was to compare immunoglobulin heavy chain variable...